Recent News

• 05.14.2025 - Inhibikase Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Activity
• 05.14.2025 - Inhibikase Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Activity
• 05.14.2025 - Inhibikase Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Activity
• 04.14.2025 - Inhibikase Therapeutics Announces Appointment of David McIntyre as Chief Financial Officer
• 04.14.2025 - Inhibikase Therapeutics Announces Appointment of David McIntyre as Chief Financial Officer
• 04.14.2025 - Inhibikase Therapeutics Announces Appointment of David McIntyre as Chief Financial Officer
• 03.27.2025 - Inhibikase Therapeutics Announces 2024 Financial Results and Highlights Recent Activity
• 03.27.2025 - Inhibikase Therapeutics Announces 2024 Financial Results and Highlights Recent Activity

Recent Filings

• 05.14.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 05.14.2025 - 8-K Current report
• 05.14.2025 - EX-99.1 EX-99.1
• 05.12.2025 - DEF 14A Other definitive proxy statements
• 05.12.2025 - ARS Annual Report to Security Holders
• 05.12.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 05.02.2025 - PRE 14A Other preliminary proxy statements
• 04.25.2025 - 10-K/A Annual report [Section 13 and 15(d), not S-K Item 405]
• 04.16.2025 - 4 Statement of changes in beneficial ownership of securities
• 04.16.2025 - 3 Initial statement of beneficial ownership of securities